Galapagos NV and Gilead Sciences announced on Wednesday the formal conclusion of their co-development and commercialisation agreement for GLPG4716, a first-in-class T cell engager program targeting severe autoimmune conditions including systemic lupus erythematosus and refractory rheumatoid arthritis. The deal, valued at up to $2.8 billion including milestone payments, was confirmed at a joint press conference held simultaneously in Foster City, California and Mechelen, Belgium.
Under the terms of the agreement, Gilead will contribute an upfront payment of $450 million and take a 50 percent co-commercialisation stake in markets across North America and Europe, while Galapagos retains primary responsibility for ongoing clinical development. The partnership grants Gilead access to Galapagos's proprietary filgotinib-era biological platform infrastructure, which the Belgian biotech has been rebuilding since its strategic pivot toward immunology in 2024.
Analysts at Morgan Stanley and Jefferies both upgraded Galapagos shares in premarket trading Wednesday, with the stock rising more than 18 percent on the Euronext Amsterdam exchange by mid-morning. The deal is seen as validation of Galapagos's post-filgotinib recovery strategy under CEO Paul Stoffels, who has spent two years repositioning the company away from its dependence on the JAK inhibitor that failed to gain full US approval in 2020.
Dr. Stoffels told investors on a morning call that Phase IIa data for GLPG4716, expected in the third quarter of 2026, would serve as a critical inflection point. 'T cell engagers have transformed oncology,' he said. 'We believe the same biological logic applies in autoimmunity, and this collaboration with Gilead gives us the resources to test that hypothesis at scale.' Gilead's Chief Scientific Officer, Flavius Martin, added that the program complemented Gilead's existing inflammation portfolio anchored by filgotinib in Europe and emerging GLP-1-adjacent metabolic disease work.
The announcement drew immediate attention from patient advocacy groups. The Lupus Foundation of America issued a statement welcoming the investment, noting that fewer than 40 percent of lupus patients achieve sustained remission under current standard-of-care regimens. With an estimated 1.5 million Americans living with lupus and global prevalence approaching five million, the commercial opportunity for an effective T cell engager therapy is substantial. Competing programmes from AstraZeneca and Sanofi are at earlier stages, leaving Galapagos and Gilead with a potential two-year clinical lead.